Articles tagged with Prostate Cancer
A study found that adding proton therapy 'boost' to X-ray radiation therapy significantly reduces prostate cancer recurrences in low- and intermediate-risk patients. The high-dose treatment also proves safe with minimal side effects, benefiting these patients with conventional doses of radiation.
A phase III study found that short-term hormone therapy added to radiation treatment significantly increases survival in medium-risk prostate cancer patients by 51% compared to those receiving radiation alone. In contrast, low-risk patients showed no significant benefit from this combination.
A phase III study found that short-term hormone therapy given prior to and during intermediate dose radiation treatment significantly increases the chance of living longer (51 percent) compared to those who receive radiation alone. The benefit appeared to be greatest for men at medium-risk for disease failure.
A U-M study found that exposure to androgen hormone relocates pieces of chromosome near each other, setting the scene for gene fusion in prostate cancer. This finding may lead to new screening tools or prevention strategies.
Researchers have developed a highly sensitive PSA assay using nanotechnology, enabling early detection of prostate cancer recurrence and improving treatment outcomes. The new technology has the potential to redefine the PSA 'zero' level, allowing for earlier diagnosis and targeted therapies.
Researchers from Germany investigated a large study of 589 prostate cancer patients between 2000 and 2006 and found no link between XMRV infection and the disease. Despite previous reports suggesting a potential association, the study detected no evidence for XMRV in German prostate cancer patients.
Researchers at Princess Margaret Hospital map a high-risk group for aggressive, 'hidden' prostate cancer, utilizing magnetic resonance imaging (MRI) to reveal tumors on the top of the prostate. The study identifies men with elevated PSA levels who benefit from MRI-guided biopsies.
Recent trials have shown small reductions in prostate cancer mortality, but the potential benefits must be balanced against increased diagnosis rates and treatment complications. Developing more effective decision support tools may improve discussions between men and their physicians about screening.
A survey found that men largely make decisions about prostate cancer screening based on conversations with clinicians, but these discussions often do not include information about the risks of testing. Statistical modeling suggests that benefits and harms of PSA screening vary with age and risk level, with higher-risk men having more p...
A Swiss study found that prostate cancer patients with lower incomes receive worse care and have a higher risk of dying from the disease. The research suggests that socioeconomic status plays a significant role in prostate cancer mortality, with poorer patients receiving less comprehensive treatment and more advanced stages at diagnosis.
A large study by Mayo Clinic researchers found that patients treated with radiotherapy after prostate cancer surgery experienced very few complications, contradicting concerns about toxicity and side effects. The study suggests that radiation treatment is an effective and safe option for patients with recurrent cancer.
A study published in the British Journal of Cancer found that 60% of prostate cancer cases lack aggressive protein Hsp-27, allowing for careful monitoring instead of treatment. The research could lead to a blood test to distinguish between aggressive and non-aggressive forms of prostate cancer.
A new study from the University of Michigan Comprehensive Cancer Center suggests that genetic risk of prostate cancer can be reduced by rescuing critical immune system cells. In mice with a gene called lymphotoxin alpha, these cells come back and delay tumor formation, potentially slowing cancer growth and spread.
A new study found that hormone therapy for prostate cancer increases the risk of developing heart problems, including coronary heart disease and heart attacks. The study suggests that doctors should consider heart-related side effects when prescribing endocrine therapy and refer patients to a cardiologist before starting treatment.
A study found improved survival rates for men with localized prostate cancer diagnosed between 1992 and 2002 compared to earlier eras. The 10-year prostate cancer-specific mortality rate was 8.3% for well-differentiated tumors, lower than previous reports.
Studies found significant DNA damage in humans with minor zinc deficiency, highlighting the health implications of inadequate intake. Experts recommend multivitamins for elderly individuals to ensure adequate levels, as zinc is essential for antioxidant defense and DNA repair.
Researchers at Columbia University Irving Medical Center found a new type of adult stem cell, CARNs, in the prostate that can give rise to cancer if tumor suppressor genes are inactivated. The discovery resolves controversy over the origin of prostate cancer cells and may help develop better treatments.
Researchers have confirmed a link between Trichomonas vaginalis and an increased risk of prostate cancer. The study found that men infected with T. vaginalis were more likely to develop extraprostatic prostate cancer and cancer that is likely to progress to bony metastases or prostate cancer-specific death.
A strong association has been found between Trichomonas vaginalis infection and advanced, lethal prostate cancer in men. The study, published on the Journal of the National Cancer Institute website, analyzed blood samples from 673 men with prostate cancer and compared infection status to 673 control subjects.
A study has found that XMRV retrovirus is present in 27% of prostate cancers, associated with more aggressive tumors. The viral proteins were predominantly found in malignant prostatic cells, suggesting a direct link between XMRV infection and tumor formation.
A new study confirms associations between SNPs and increased prostate cancer risk in Japanese men, similar to findings in European populations. Men with six or more risk alleles had substantially higher risk for prostate cancer.
A new study published in The Journal of Nuclear Medicine shows that PET/CT scans with the imaging agent choline can detect recurring prostate cancer sooner than conventional imaging technologies. Researchers found a strong association between PET/CT detection and PSA levels, and suggest using specific criteria to reduce unnecessary scans.
Researchers estimated that 1.3 million extra cases were diagnosed and over a million treated since 1986 due to overdiagnosis of prostate cancer through PSA screening. The majority of these cases involve younger men.
A new study found that men diagnosed with low-risk prostate cancers who deferred treatment were still doing fine an average of eight years after their diagnosis. Only half of these men eventually underwent any treatment 10 to 15 years post-diagnosis, preserving their quality of life.
A recent study found that the racial disparity gap in prostate cancer stage at diagnosis has decreased over time. More men were diagnosed with prostate cancer at an earlier age and stage in 2004-2005 compared to earlier years, according to data from the Surveillance, Epidemiology, and End Results program.
Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or along with radiation therapy for prostate cancer have a higher risk of death, according to a study. However, in men without comorbidities, hormone therapy was not associated with an increased risk of all-cause mortality.
A new study has found that high serum insulin levels are associated with an increased risk of prostate cancer, even within the normal range. Insulin-like growth factors may play a role in prostate cancer development.
Researchers at USC have identified novel genetic mechanisms that govern an individual's risk of developing prostate cancer, highlighting the role of gene 'deserts' and regulatory sequences. The study found that genetic variations in these regions can modulate gene expression, increasing the risk for certain diseases.
A new study has found that obesity increases the risk of prostate cancer recurrence in both black and white men, with no racial difference observed. Researchers analyzed data from 1,415 patients and found a significant association between higher body mass index and increased risk of cancer recurrence.
A new study found that denosumab significantly increased bone density at all monitored sites and reduced new vertebral fractures by 62% in men receiving androgen-deprivation therapy for prostate cancer. The treatment also showed improvements in bone density at the radius, one of the bones in the forearm.
Oral sodium clodronate reduces death by 23% and increases overall survival to 30% at 5 years for patients with advanced prostate cancer. However, in men with localized disease, clodronate shows no improvement in overall survival.
A new study by Louis Potters and colleagues found that permanent prostate brachytherapy is an effective treatment option for younger patients diagnosed with prostate cancer, with success rates comparable to older patients. The study analyzed data from 2,119 patients and showed that age didn't impact the long-term therapeutic outcome of...
The North Carolina-Louisiana Prostate Cancer Project finds differences in physician trust, access to care, and continuity of care between African American and Caucasian men, leading to advanced prostate cancer at diagnosis. An established relationship with a healthcare provider can mitigate these disparities.
A University of North Carolina study found that establishing a regular relationship with a healthcare provider reduces racial disparities in prostate cancer diagnosis. Men with ongoing relationships are more likely to receive screenings and less likely to be diagnosed with advanced disease.
Researchers have identified MEK4 as a key player in promoting cell invasion in prostate cancer. Genistein, a dietary compound, inhibits MEK4 kinase activity, suggesting potential therapeutic applications for prostate cancer treatment.
A large-scale study found that only 12% of men who underwent radical prostatectomy between 1987 and 2005 died from prostate cancer within 15 years. The low mortality rate suggests that some patients with slow-growing cancers may not need immediate treatment.
A recent study published in Cancer found that men with early stages of prostate cancer who delay radical treatment have acceptable levels of anxiety and distress. The study's results suggest that living with untreated cancer is not upsetting for many patients, but certain mental and physical factors can increase distress.
Developed a compact gamma camera called ProxiScan to localize prostate cancer tissue with high resolution. The camera system enables early diagnosis and treatment of potentially deadly disease.
Researchers have discovered a new gene fusion, NDRG1-ERG, that produces a protein potentially targeted by drug therapies. This finding may improve prostate cancer testing and treatment options.
Researchers at Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveal how late-stage prostate tumors gain ability to grow without hormones. The study identifies a gene called UBE2C as key regulator in hormone-independent growth.
Researchers found that finasteride use made no difference in high-grade cancer rates among men without cancer warning signs, but significantly reduced the risk in those with abnormal digital rectal exams or elevated PSA levels. The study suggests doctors can be less cautious in using finasteride for preventive treatment.
Dr. Nima Sharifi received a $375,000 grant to study genes that determine prostate cancer resistance to androgen deprivation therapy. The funding supports his laboratory's work in developing new therapies.
A new molecule finds and penetrates prostate cancer cells, allowing for targeted treatment and improved imaging. The targeting molecule has the potential to reduce toxic side effects and improve diagnosis of prostate cancer.
A new three-way measurement method has been developed to predict disease metastasis in prostate cancer, combining PSA doubling time, Gleason score, and interval between surgery and detectable PSA levels. This improved prediction method may help determine which patients benefit from additional therapy after surgery.
The July issue of European Urology reviews prostate cancer screening studies, highlighting the need to balance mortality reduction with overdiagnosis risks. The EAU adopts the conclusions of the ERSPC study and recognizes the benefit of screening for mortality reduction.
A study by Dana-Farber Cancer Institute found that higher selenium levels can worsen prostate cancer outcomes for men carrying a specific SOD2 gene variant. Men with the highest selenium levels and this variant had a 40% lower risk of aggressive disease, while those with the lowest levels were twice as likely to develop it.
Sexual medicine experts focus on treating causes of sexual dysfunction beyond physical issues, exploring relationship dynamics and hormonal imbalance. New treatments and options for women and men are being developed to address complex sexual health needs.
The Prostate Cancer Translational Research in Europe meeting showcased ongoing research efforts to identify biomarkers, genetic variants and new therapeutic options. Researchers discussed the importance of collaboration between clinicians and scientists to streamline current efforts and avoid duplication.
A recent study published in Cancer Prevention Research found that men with prostate cancer who consumed green tea demonstrated a significant reduction in serum markers predictive of disease progression. The study showed a 30% or greater reduction in levels of hepatocyte growth factor, vascular endothelial growth factor, and prostate-sp...
Researchers used a combination of an immunotherapeutic agent called MDX-010 or ipilimumab with standardized hormone treatment and radiation therapy to treat advanced prostate cancer. The approach led to significant tumor shrinkage and cancer cell death, allowing surgery in two previously inoperable patients.
Researchers have developed a novel form of treatment using an alpha-particle emitting radiopeptide that targets and destroys cancer cells while sparing healthy tissue. The study found that this therapy was significantly more effective at tripling the survival rate of mice with recurrent prostate cancer compared to traditional treatments.
A new online decision tool allows prostate cancer patients to weigh their own preferences against medical data to personalize treatment plans. The tool considers multiple factors, including life expectancy and side effects, to guide treatment decisions.
A new risk assessment test, CAPRA, has been developed to predict long-term risks and pinpoint high-risk cases in prostate cancer. The test accurately predicted bone metastasis, prostate cancer-specific mortality, and all-cause mortality when localized prostate cancer is first diagnosed.
A recent study found that hormone therapy can alter prostate tumor properties, making them more aggressive and prone to metastasis. The treatment reduces male sex hormone production, but also increases levels of proteins enabling cancer cells to spread.
A four-year UCLA study found significant impacts on quality of life for prostate cancer patients treated with radical prostatectomy, seed implants, or external beam radiation. The study developed 'probability plots' to predict when side effects will return to normal or if a patient will fully recover.
Two studies found that patients with cancer aged 65+ experience a significant decline in physical and mental health, leading to lower overall quality of life. The impact on HRQOL was quantified by analyzing changes in patients' well-being before and after diagnosis.
A new study has found that autoantibodies are not strongly associated with improved outcomes in melanoma patients treated with interferon. The CAPRA score was accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause mortality at diagnosis of localized prostate cancer.
Researchers at Baylor College of Medicine discovered changes in 1,141 genes that induce the formation of new structures such as blood vessels and nerves in prostate cancer patients. These gene changes may explain why men with reactive stroma face a more aggressive disease.
A diet rich in fruits and vegetables, such as tomatoes, cauliflower, and broccoli, may help prevent prostate cancer. Avoiding high-energy intake, excessive meat, dairy products, and calcium may also be beneficial.
A new technique using gold nanoparticles could lead to an effective and affordable over-the-counter prostate cancer test kit. The test is designed to detect cancer-producing proteins related to prostate cancer, similar to the FDA-approved Prostate-Specific Antigen (PSA) test.